ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Varmus Appoints Group On Intellectual Property

May 8, 1998

Ohio State, Hawaii Name New Center Directors; Berlin Acting Director At Papanicolaou

July 29, 1988

In Brief: Visco Elected Chairman of DOD Panel; Breast Cancer Stamp Raises $4.9 Million

February 19, 1999

Markison leaving Bristol-Myers, two others promoted in reorganization.

January 30, 2004

White House FY 1979 Budget Probably Will give NCI $900 Million; NCAB Objects To ’78 Allocations

November 25, 1977

ACCC Established FCCC Special Interest Group

April 11, 1986